I don't dare to think of all 60 or $600m in revenue as that...

I don't dare to think of all 60 or $600m in revenue as that implies NPAT of more than $400m and at a PE of 10x a market cap of $4b or $5 per share.

I am hoping maybe 10 or 20 or 30 sign over then next 3 years - if they are all small research firms then revenue is likely to average only 2-5m for each so nothing like the $600m figure. To achieve this we need the large IVD signings worth $20m+

I am just looking for the first milestone of 1,2 or 3 small research signatures that take us cash flow positive by 2013 (would need these by the middle of the year given cash flow lag). It is possible that one alone could take us cash flow positive but I suspect a couple would be safer.

The really big ones with product life cycles and process changes required could sign this year but it would be an 18 month ramp up to maximum cash flow for ADO.

The MACD is about to turn up again so we are probably about to run like we did early Dec - hopefully with substance this time. The air is electric with anticipation and it certain does appear that a little SP manipulation is going on.